Bode, D., Semmler, L., Wakula, P., Hegemann, N., Primessnig, U., Beindorff, N., . . . Hohendanner, F. (2021). Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF. Cardiovasc Diabetol.
Chicago Style CitationBode, David, et al. "Dual SGLT-1 and SGLT-2 Inhibition Improves Left Atrial Dysfunction in HFpEF." Cardiovasc Diabetol 2021.
MLA CitationBode, David, et al. "Dual SGLT-1 and SGLT-2 Inhibition Improves Left Atrial Dysfunction in HFpEF." Cardiovasc Diabetol 2021.
Warning: These citations may not always be 100% accurate.